Long-term occurrence of death and cardiovascular events in patients with transient ischaemic attack or minor ischaemic stroke: comparison between arterial and cardiac source of the index event

Background and aim: Published data suggest that patients with cerebral ischaemia and atrial fibrillation (CIAF) have higher inhospital mortality than patients with cerebral ischaemia of arterial origin (CIAO). Data on long term risks are scarce. We compared the long term risks of death and vascular events (VE) between these groups. Methods: We extended the follow-up of 2473 patients from the Dutch TIA Trial (recruitment March 1986 to March 1989, all treated with aspirin; CIAO) and 186 Dutch participants of the European Atrial Fibrillation Trial (recruitment June 1988 to May 1992, 26% on anticoagulants during the trial; CIAF). Hazard ratios (HRs) for death and VE of CIAF versus CIAO were analysed by means of Cox regression analysis and adjusted for age, sex and several cardiovascular risk factors. Results: After a mean follow-up of 10.1 years, 1484 patients with CIAO had died and 1336 had suffered at least one VE (377 cardiac, 455 stroke). Mean follow-up of the CIAF patients was 6.8 years; 150 patients had died and 136 had suffered at least one VE (41 cardiac, 63 stroke). Adjusted HRs (CIAF vs CIAO) were 1.46 (95% CI 1.22 to 1.74) for death, 1.49 (1.24 to 1.79) for first VE, 1.94 (1.47 to 2.55) for first stroke and 1.41 (1.01 to 1.96) for first cardiac event. These HRs were essentially the same as those for the duration of the trials. Conclusion: Our study shows that the long term risk of death or vascular events is 1.5 times higher in patients with CIAF than in those with CIAO, after adjustment for differences between the groups.

[1]  A. Algra,et al.  Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial , 2006, The Lancet.

[2]  A. Algra,et al.  Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study , 2005, The Lancet.

[3]  Claudia Stöllberger,et al.  Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke registry. , 2004, European heart journal.

[4]  R. Kronmal,et al.  Lessons from the Stroke Prevention in Atrial Fibrillation Trials , 2003, Annals of Internal Medicine.

[5]  J. Riancho,et al.  Atrial fibrillation as a risk factor for stroke recurrence. , 2003, The American journal of medicine.

[6]  A. Connor,et al.  The way I see it: House officers need formal career development , 2002 .

[7]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[8]  Catherine Sudlow,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[9]  H. Diener,et al.  Risk Factors, Outcome, and Treatment in Subtypes of Ischemic Stroke: The German Stroke Data Bank , 2001, Stroke.

[10]  P. Sandercock,et al.  Risk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial , 2001, Stroke.

[11]  J. Rothrock,et al.  Cardioembolic vs. Noncardioembolic Strokes in Atrial Fibrillation: Frequency and Effect of Antithrombotic Agents in the Stroke Prevention in Atrial Fibrillation Studies , 2000, Cerebrovascular Diseases.

[12]  O. Benavente,et al.  Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.

[13]  D. Sherman,et al.  Atrial fibrillation and stroke. , 1997, Stroke.

[14]  V. Salomaa,et al.  Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. , 1997, Stroke.

[15]  A. Algra,et al.  Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[16]  L. Wilkins.  Trial of Secondary Prevention With Atenolol After Transient Ischemic Attack or Nondisabling Ischemic Stroke , 1993, Stroke.

[17]  J. Slattery,et al.  Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project) , 1992, BMJ.

[18]  J. Broderick,et al.  Relationship of Cardiac Disease to Stroke Occurrence, Recurrence, and Mortality , 1992, Stroke.

[19]  A. Algra,et al.  A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. , 1991, The New England journal of medicine.

[20]  P. Wolf,et al.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. , 1991, Stroke.

[21]  M. Britton,et al.  Pathogenetic mechanism of stroke in non‐valvular atrial fibrillation: follow‐up of stroke patients with and without atrial fibrillation , 1991, Journal of internal medicine.

[22]  H. Schouten,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[23]  L. Goldman,et al.  Thromboembolism in patients with atrial fibrillation. , 1984, Archives of neurology.

[24]  J. Sage,et al.  Risk of recurrent stroke in patients with atrial fibrillation and non‐valvular heart disease. , 1983, Stroke.

[25]  A. Belanger,et al.  The Framingham study. , 1976, British medical journal.

[26]  J. Swieten.  Interobserver Agreement for the Assessment of Handicap in Stroke Patients , 2005 .

[27]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[28]  R. Bloch,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.